CO4910113A1 - Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion - Google Patents

Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion

Info

Publication number
CO4910113A1
CO4910113A1 CO97067661A CO97067661A CO4910113A1 CO 4910113 A1 CO4910113 A1 CO 4910113A1 CO 97067661 A CO97067661 A CO 97067661A CO 97067661 A CO97067661 A CO 97067661A CO 4910113 A1 CO4910113 A1 CO 4910113A1
Authority
CO
Colombia
Prior art keywords
preparation
dalphopristine
quinu
pristine
pharmaceutical compositions
Prior art date
Application number
CO97067661A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Paul Bounine
Guillaume Conrath
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of CO4910113A1 publication Critical patent/CO4910113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO97067661A 1996-11-19 1997-11-19 Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion CO4910113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614062A FR2755857B1 (fr) 1996-11-19 1996-11-19 Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation

Publications (1)

Publication Number Publication Date
CO4910113A1 true CO4910113A1 (es) 2000-04-24

Family

ID=9497744

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97067661A CO4910113A1 (es) 1996-11-19 1997-11-19 Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion

Country Status (44)

Country Link
US (1) US5994338A (enExample)
EP (1) EP0949923B1 (enExample)
JP (1) JP4278115B2 (enExample)
KR (1) KR100530836B1 (enExample)
CN (1) CN1146417C (enExample)
AP (1) AP998A (enExample)
AR (1) AR008695A1 (enExample)
AT (1) ATE223217T1 (enExample)
AU (1) AU740291B2 (enExample)
BG (1) BG63621B1 (enExample)
BR (1) BR9713087A (enExample)
CA (1) CA2271095C (enExample)
CO (1) CO4910113A1 (enExample)
CZ (1) CZ299913B6 (enExample)
DE (1) DE69715247T2 (enExample)
DK (1) DK0949923T3 (enExample)
DZ (1) DZ2349A1 (enExample)
EA (1) EA002025B1 (enExample)
EE (1) EE03668B1 (enExample)
ES (1) ES2179375T3 (enExample)
FR (1) FR2755857B1 (enExample)
HR (1) HRP970615B1 (enExample)
HU (1) HUP9904327A3 (enExample)
IL (2) IL129607A0 (enExample)
IN (1) IN187038B (enExample)
JO (1) JO1992B1 (enExample)
MA (1) MA26448A1 (enExample)
MY (1) MY123805A (enExample)
NO (1) NO992399D0 (enExample)
NZ (1) NZ334949A (enExample)
OA (1) OA11047A (enExample)
PE (1) PE13999A1 (enExample)
PL (1) PL190164B1 (enExample)
PT (1) PT949923E (enExample)
RS (1) RS49608B (enExample)
SA (1) SA97180645B1 (enExample)
SK (1) SK284311B6 (enExample)
TN (1) TNSN97184A1 (enExample)
TR (1) TR199901096T2 (enExample)
TW (1) TW474816B (enExample)
UA (1) UA59376C2 (enExample)
UY (1) UY24780A1 (enExample)
WO (1) WO1998022107A1 (enExample)
ZA (1) ZA9710435B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US6119269A (en) * 1999-09-23 2000-09-19 Imler; Jack Fishing vest with removable storage container system
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
FR2812549B1 (fr) * 2000-08-03 2003-03-21 Aventis Pharma Sa Associations dalfopristine/quinupristine avec le cefpirome
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549065B1 (fr) * 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2576022B1 (fr) * 1985-01-11 1987-09-11 Rhone Poulenc Sante Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2599036B1 (fr) * 1986-05-22 1988-09-09 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO1998022107A1 (fr) 1998-05-28
YU22499A (sh) 2002-03-18
KR100530836B1 (ko) 2005-11-23
HUP9904327A3 (en) 2002-03-28
CA2271095A1 (fr) 1998-05-28
IL129607A (en) 2006-08-20
CZ174899A3 (cs) 1999-08-11
DZ2349A1 (fr) 2002-12-28
JP2001504475A (ja) 2001-04-03
AU5125698A (en) 1998-06-10
HRP970615B1 (en) 2002-12-31
DK0949923T3 (da) 2002-12-23
CN1233959A (zh) 1999-11-03
ES2179375T3 (es) 2003-01-16
SK66099A3 (en) 2000-01-18
UY24780A1 (es) 2001-08-27
DE69715247D1 (de) 2002-10-10
CZ299913B6 (cs) 2008-12-29
AU740291B2 (en) 2001-11-01
BG103412A (en) 2000-06-30
HRP970615A2 (en) 1998-08-31
MA26448A1 (fr) 2004-12-20
EP0949923A1 (fr) 1999-10-20
OA11047A (fr) 2003-03-07
TR199901096T2 (xx) 1999-07-21
PE13999A1 (es) 1999-05-05
NO992399L (no) 1999-05-19
IN187038B (enExample) 2001-12-29
TNSN97184A1 (fr) 2005-03-15
NO992399D0 (no) 1999-05-19
ZA9710435B (en) 1998-06-10
NZ334949A (en) 2000-12-22
SA97180645B1 (ar) 2005-12-12
UA59376C2 (uk) 2003-09-15
DE69715247T2 (de) 2003-04-30
US5994338A (en) 1999-11-30
IL129607A0 (en) 2000-02-29
FR2755857A1 (fr) 1998-05-22
TW474816B (en) 2002-02-01
PT949923E (pt) 2003-01-31
CN1146417C (zh) 2004-04-21
EE03668B1 (et) 2002-04-15
HUP9904327A2 (hu) 2000-06-28
SK284311B6 (sk) 2005-01-03
KR20000053343A (ko) 2000-08-25
CA2271095C (fr) 2004-08-03
ATE223217T1 (de) 2002-09-15
EA199900479A1 (ru) 2000-02-28
BR9713087A (pt) 2000-03-28
EE9900127A (et) 1999-12-15
AP998A (en) 2001-08-09
RS49608B (sr) 2007-06-04
EP0949923B1 (fr) 2002-09-04
AR008695A1 (es) 2000-02-09
BG63621B1 (bg) 2002-07-31
JO1992B1 (en) 1999-05-15
PL190164B1 (pl) 2005-11-30
JP4278115B2 (ja) 2009-06-10
HK1022832A1 (en) 2000-08-25
MY123805A (en) 2006-06-30
FR2755857B1 (fr) 1998-12-24
EA002025B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
DE69705300D1 (de) Cyclopropylalkansäurederivate
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
MY115662A (en) Novel compounds with analgesic effect
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
DE3679128D1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
IS5501A (is) Samsetningar og aðferðir til að auka styrkinn og/eða hreyfanleikan hjá sæðisfrumum í manneskjum
HUP0002106A2 (hu) Transz-5-klór-2,3,3a,12b-tetrahidro-2-metil-1H-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol aromás szulfonátjai és az ezt tartalmazó gyógyszerkészítmények
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
UY24780A1 (es) Composiciones farmacéuticas estabilizadas a base de quinupristina y dalfopristina y su preparación.
ID17875A (id) Komposisi farmasi yang mengandung asam 4-oksobutanoat
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores
AP9801235A0 (en) Erythromycin derivatives.
DE58909140D1 (de) Verwendung stabiler Oxapenem-3-carbonsäuren zur Herstellung Beta-Lactamase hemmender Arzneimittel.
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
RU93052408A (ru) Ациламино-алкилиден-гидрокси-бис-фосфоновые кислоты, способ их получения, фармацевтическая композиция
IS3947A (is) Amínósýru afleiður, aðferð til framleiðslu þeirraog notkunar sem lyfja
BG104162A (en) Pharmaceutical composition active in the reduction of the mcp-1 protein production
BR9908401A (pt) Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural